ACE and Abnormal heart morphology: Recent advancements in the medical management of congenital heart defects (CHDs) include the use of prostaglandins, angiotensin-converting enzyme inhibitors, and selective pulmonary vasodilators, such as inhaled nitric oxide and endothelin receptor antagonists.